Veradermics, Incorporated (MANE )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol MANE
- Company Veradermics, Incorporated
- Price $111.32
- Changes Percentage 5.19
- Change 5.49
- Day Low $105.01
- Day High $117.81
- Year High $117.71
- Year Low $32
- Market Cap $4,041,670,180
- Price Avg 50 EMA (D) $86.14
- Price Avg 200 EMA (D) $71.05
- Exchange NYSE
- Volume 579,037
- Average Volume 569,464
- Open $108.51
- Previous Close $105.83
- EPS -2.65
- PE -36.51
- Earnings Announcement 2026-06-03 12:00:00
- Shares Outstanding $41,778,687
Company brief: VERADERMICS, INCORPORATED (MANE )
- Healthcare
- Biotechnology
- Reid Waldman
- https://www.veradermics.com
- US
- N/A
- 12-30-2008
- US9229671048
Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy. Additionally, it engages in the development of VDMN, a dissolvable microarray patch technology for immunotherapy of common warts; VDAA for the treatment of alopecia areata; and VDMC for the treatment of molluscum contagiosum. Its products are used for the treatment of androgenetic alopecia, common warts, molluscum contagiosum, alopecia areata, and atopic dermatitis. The company serves healthcare providers and clinicians treating dermatologic and aesthetic conditions in both adult and pediatric populations, as well as the broader medical and clinical research community involved in dermatology. Veradermics, Incorporated was founded in 2019 and is based in New Haven, Connecticut.